Natural vs. Synthetic 7-OH: Why the Molecule Is Identical

On May 11, 2026, in the Oval Office, the President told reporters his administration would "seek to have natural 7-OH approved." Inside 48 hours, two camps inside the kratom industry pulled the quote in opposite directions.

The American Kratom Association and several "natural leaf" trade groups read "natural" as whole leaf only — the dried Mitragyna speciosa material that contains roughly 2% 7-hydroxymitragynine by weight. By their definition, any product that concentrates 7-OH past that natural ratio is "synthetic" and outside what the administration endorsed.

The Holistic Alternative Recovery Trust (HART) and most 7-OH manufacturers read it the opposite way — that the White House endorsed all 7-OH, including 96%-pure concentrates, because the molecule itself originates in the kratom plant and is also produced naturally inside the human body when the liver metabolizes mitragynine.

Mac Haddow of the AKA called the second interpretation "a big con job."

The chemistry has a clearer answer than either side has been willing to lay out plainly. And it sounds a lot like a fight the cannabis industry settled a decade ago.

What 7-OH actually is, biochemically

Mitragyna speciosa leaf contains more than 40 alkaloids. Two matter for this debate:

• Mitragynine — the dominant alkaloid, typically 60-70% of total alkaloid content in dried leaf.
• 7-hydroxymitragynine (7-OH) — a minor alkaloid in fresh and dried leaf, typically present at 1-2% of total alkaloid content.

7-OH is the alkaloid that does most of the analgesic work. It binds the mu-opioid receptor with roughly 13× the potency of morphine in receptor-binding assays.^[1] Mitragynine, by contrast, is a relatively weak direct mu-opioid agonist on its own.

The catch — and this is where the "synthetic" label collapses — is what happens inside the human body when you ingest mitragynine.

Your liver converts mitragynine to 7-OH

When a person chews a fresh leaf, drinks kratom tea, or swallows a leaf-powder capsule, the dominant alkaloid going in is mitragynine. The liver's cytochrome P450 3A4 enzyme then performs a single hydroxylation step that converts a fraction of that mitragynine into 7-hydroxymitragynine.^[2] This is well-established pharmacology — published across multiple peer-reviewed journals.

So a person who only ever consumes whole leaf is still getting their analgesic effect from 7-OH. Their body just made it on the way through, instead of receiving it pre-formed. The molecule binding the receptor is identical either way — same stereochemistry, same potency, same metabolic fate downstream.^[3]

This is the central biochemical fact the "natural leaf only" camp has to argue around. The active compound delivering the effect of "natural" kratom is 7-OH. Calling 7-OH itself "unnatural" requires also calling your own liver an unnatural process.

What concentration actually means

"Concentrated 7-OH" can mean a few different things depending on the manufacturer. The honest categories:

1. Selective extraction. Use a solvent — water, ethanol, or a food-grade non-polar solvent — to pull the alkaloid fraction out of plant material, then evaporate the solvent. You end up with a 30-60% alkaloid extract that preserves the natural ratio of mitragynine to 7-OH. Nothing is converted; the chemistry of each molecule is unchanged.

2. Alkaloid isolation. Use chromatography to separate the individual alkaloids in an extract from each other. Now you can collect a fraction that is, say, 96% 7-OH. Again, no chemistry has been performed on the molecule. It is the same compound your liver makes from mitragynine, the same compound that exists in the leaf, just concentrated and purified.

3. Mitragynine-to-7-OH conversion. This is the step where the debate gets honest. Some manufacturers start from mitragynine (which is cheap and abundant in leaf) and run a single oxidation step to add a hydroxyl group at the 7-position — producing 7-OH. The reaction conditions vary; the product is chemically identical to the 7-OH your liver produces and to the 7-OH that exists in fresh leaf. Same molecule, same stereochemistry, same receptor activity.

None of these three is "synthetic" in any meaningful chemistry definition of the word. Synthetic, in pharmacology, means a compound built de novo — assembled from simple precursors that bear no resemblance to the final molecule. Fentanyl is synthetic. Nitazene analogs are synthetic. Converting mitragynine to its own hydroxylated metabolite is not synthesis — it's the same step the liver performs in every person who has ever chewed a kratom leaf.^[2]

The parallel cannabis already lived through

The cannabis industry had this exact argument ten years ago over THCA and THC.

Raw cannabis flower contains almost no Δ9-THC. It contains THCA — tetrahydrocannabinolic acid — which is non-intoxicating. When cannabis is heated (smoking, vaporizing, baking into edibles), THCA undergoes decarboxylation: it loses a carboxyl group as CO₂ and becomes THC. That's a single chemical change. The THC in a properly made edible is the exact same molecule produced when raw flower is heated; it is also the exact same molecule that exists naturally in cured, aged cannabis where slow decarboxylation has occurred at room temperature.

For years, prohibitionists argued that THC edibles were "synthetic" or "manufactured" because the conversion happened in a commercial kitchen instead of a lighter flame. The argument lost — not because of politics, but because the chemistry didn't support it. Decarboxylating THCA in a controlled facility produces a more accurately dosed, more rigorously tested THC product than smoking flower of unknown potency. Lab testing, alkaloid identity verification, and contaminant screening became the industry's quality floor.

The 7-OH industry is now standing exactly where the THC-edible industry stood in 2014. Same chemistry argument. Same "natural vs. synthetic" framing from incumbents whose business model depends on the distinction. Same eventual answer: test the product, verify the molecule, screen for contaminants, label honestly.

What the misinformation actually is

It is not misinformation to say "concentrated 7-OH products carry different risks than chewing a leaf." That's true. A 96%-pure 7-OH tablet at 12 mg delivers a dose that would require eating a meaningful fraction of a plant to match through mitragynine metabolism.^[4] Dose and onset matter. Standardization matters. Testing matters.

It is misinformation to say concentrated 7-OH is "synthetic" or that the molecule itself is somehow different from the 7-OH in leaf or the 7-OH your body makes. Those claims rely on the public not knowing what the word "synthetic" means in chemistry. They are designed to confuse — to map a regulatory boundary the speaker prefers ("only leaf-form products should be legal") onto a chemistry boundary that does not exist.

The same playbook was used against THC edibles, against high-CBD isolate products, against nicotine pouches versus combustible tobacco. In each case, the "natural" framing did real damage in the short term and lost in the long term once independent chemistry and testing entered the conversation.

What sound chemistry and testing look like in 2026

The defensible position — the only position that holds up if scheduling decisions are made on science instead of marketing — is this:

• Verify the molecule. ISO/IEC 17025-accredited labs can confirm whether a product contains pure 7-hydroxymitragynine, whether the stereochemistry is correct, and whether any unexpected analogs or contaminants are present.
• Verify the alkaloid panel. A real Certificate of Analysis lists every alkaloid detected at quantifiable concentration, not just a single headline number. If a product claims "97% 7-OH," the COA should show the other 3%.
• Verify contamination. Heavy metals (ICP-MS), residual solvents, microbial contaminants, and elemental impurities all need their own panels with pass/fail thresholds tied to recognized standards.
• Publish per batch. One COA at product launch doesn't mean anything. A real testing program publishes a new COA for every production lot, with the lot number printed on the bottle.

This is what Favor'd Alkz publishes for every batch of every product — full-panel ISO/IEC 17025 Certificates of Analysis from Cora Science (PJLA #116374), tied to lot numbers on the bottle. The point is not the marketing. The point is that when regulators, researchers, and the public ask "what is in this product," there is an independent, accredited answer that does not depend on which industry talking point happens to be winning that week.

Why this fight matters beyond the kratom industry

The administration's ambiguous "natural 7-OH" comment landed in the middle of a debate the kratom industry was already having about its own quality floor. The bad actors in the market — the gas-station tablets with no testing, the unlabeled blends, the products selling at doses that would alarm any pharmacologist — give cover to scheduling proposals that would also wipe out the manufacturers running real lab programs.

The natural-leaf camp's framing offers a clean political answer: ban the concentrates, keep the leaf, problem solved. The trouble is that the framing is not chemistry. It is a regulatory preference dressed up as a natural-product argument. Honest concentrates with full third-party testing are safer, more predictable, and more honestly labeled than the leaf products the framing tries to protect — because the testing infrastructure exists and the alkaloid content is verifiable.

The industry's path forward is not picking a side in a "natural vs. synthetic" argument that the chemistry doesn't support. It is making the testing floor non-negotiable. Verify the molecule. Verify the panel. Publish per batch. Let regulators make policy on what the lab data shows — not on which side has the better lobbying budget.

The cannabis industry took ten years to learn this lesson. The 7-OH industry doesn't have ten years.

Sources

1. Kruegel AC, Gassaway MM, Kapoor A, et al. "Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators." Journal of the American Chemical Society, 2016;138(21):6754–6764. doi:10.1021/jacs.6b00360
2. Kamble SH, Sharma A, King TI, et al. "Metabolite Profiling and Identification of Enzymes Responsible for the Metabolism of Mitragynine, the Major Alkaloid of Mitragyna speciosa (Kratom)." Drug Metabolism and Disposition, 2019;47(10):1108–1116. doi:10.1124/dmd.118.085126
3. Váradi A, Marrone GF, Palmer TC, et al. "Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2." ACS Chemical Neuroscience, 2016;7(9):1257–1266. doi:10.1021/acschemneuro.6b00175
4. Bhowmik S, Galeta J, Bhowmik D, Bhatt M. "Pharmacology of Kratom: In Vitro Studies, Clinical Observations, and Regulatory Perspectives." Pharmacology Research & Perspectives, 2021;9(4):e00555. doi:10.1002/prp2.555

Favor'd Alkz publishes full-panel ISO/IEC 17025 Certificates of Analysis for every batch of every product, tied to the lot number on the bottle. View our published COAs.